Attovia Therapeutics, a clinical-stage biopharmaceutical company, focuses on developing treatments for immune system diseases using its proprietary ATTOBODY biologics platform.
The company's Initial Public Offering (IPO) was significantly upsized, resulting in the sale of 19.55 million shares, including an option exercised by underwriters.
The successful IPO generated approximately $332.40 million in gross proceeds, with the stock opening at $21.00 per share and reaching a new 52-week high of $22.05.
Attovia Therapeutics (NASDAQ:ATTO) is a clinical-stage biopharmaceutical company that started in 2023. It focuses on creating new treatments for diseases caused by the immune system. The company develops its potential products using the ATTOBODY biologics platform, which it licenses from Alamar Biosciences.
The company recently priced its Initial Public Offering (IPO), which is when a private company first sells shares to the public. As highlighted by GlobeNewswire, Attovia initially planned to offer 17 million shares of its common stock to the public at a price of $17.00 per share.
The offering was later upsized, meaning more shares were sold than originally planned. The final offering included 19.55 million shares. This amount includes an additional 2.55 million shares purchased by the underwriters. Underwriters are financial institutions that help manage the IPO, and their option allows them to buy extra shares at the offering price.
This upsized IPO generated gross proceeds of approximately $332.40 million for Attovia. Gross proceeds represent the total money raised from the sale before any expenses, such as underwriting fees, are deducted. The stock began trading on the Nasdaq on August 5, 2026, opening at $21.00 per share. Currently, shares of Attovia trade at $20.38. The stock's price has moved between a low of $19.71 and a high of $22.05 during the day.
